[PDF] Top 20 Cellular immunotherapy for refractory hematological malignancies

... Discussion Cellular Immunotherapy for Refractory Hematological Malignancies provides a novel treatment for patients with relapsed and refractory acute leukemia or aggres- sive ... See full document

... cure malignancies, different approaches have been recently developed to further improve NK cell activation through this ...cure refractory B-CLL [ 200 ... See full document

... Many adoptive immunotherapies using various killer cells, i.e., standard lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TILs), have merely shown limited efficacy in clinical trials, due to ... See full document

... In AML, the functional relevance of the miR-29 calls for the rationale to use its mimics in the management of AML patients [142,143]. MiR-29b-1 interplays with AML1-ETO, the oncogenic fusion protein encoded by the ... See full document

... and Refractory Multiple Myeloma ...recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML) and in this report highlight the new drugs and companies developing ... See full document

... Mice knocked out for PKC-β expression were refractory to CLL transplantation, highlighting the relevance of this novel mechanism in vivo in the tumor microenvironment. Two points are worth mentioning, i) part of ... See full document

... to prevent long term disabilities. Research into the mech- anism of action of thalidomide unraveled an immunolog- ical and immunomodulatory basis for the effect, notably inhibition of denovo IgM antibody synthesis[2] by ... See full document

... The development of chemotherapeutic resistance is one of the major factors that contribute to cancer mortality. Though a combination of molecular mechanisms is responsible for drug resistance, the role played by EV in ... See full document

... Recently cellular signaling pathway inhibitors have been approved, the Bruton tyrosine kinase inhibitor ibrutinib, phosphatidylinositol-3 kinase delta inhibitor idelalisib and the Bcl-2 inhibitor venetoclax, that ... See full document

... Daily navitoclax was also evaluated in patients with re- lapsed or refractory CLL. Navitoclax showed anti- leukemic activity against CLL, but a more heterogeneous pattern of response was observed when compared ... See full document

... 67. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, ... See full document

... There were some limitations to this study. First, we tried to investigate all the adult patients with hematological malignancies. However, this study is a retrospective cohort in a single university ... See full document

... 2 ABSTRACT The Telomere is a nucleoprotein complex consisting of TTAGGG repeated sequences covered by specialized binding proteins termed shelterins masking the end of linear chromosomes and thereby protecting the end ... See full document

... hematologic malignancies Although immunotherapy has shown success in a wide variety of cancers including many solid tumors, there are some unique features of hematologic malignancies in this setting ... See full document

... 2.2. Anticancer vaccines At present, there are no FDA-approved tumor vaccinations for melanoma. The aim of this technique is to facilitate tumor antigen recognition and a subsequent anti-tumor immune response by ... See full document

... and cellular interactions, it is imperative to further elucidate and understand the distinct roles that different galectins may play in the biology of hematologic neoplasms before they could be develop as ... See full document

... attaining cellular immortality and may therefore be a critical step in ...promote cellular immortality, thereby contributing to the malignant ...in hematological neoplasms, ... See full document

... the hematological malignancies, attempting to group these diseases in three categories: lymphomas, myelodysplastic syndromes, and acute myelogenous leukemia and ...or refractory patients and tend to ... See full document

... Conclusions Immunotherapies have expanded the treatment options available for patients with genitourinary malignancies. With the availability of checkpoint inhibitors, durable responses are seen in patients with ... See full document

... on CAR T-cell production. Common cancers that have clinical analogues in humans and dogs. 1.7 million human patients) get diagnosed with cancer each year, representing ca.. © 20[r] ... See full document